Biomarker analysis has revealed that dupilumab treatment in patients with CRSwNP reduced concentrations of type 2 inflammatory biomarkers including eotaxin-3, periostin, eosinophil cationic protein (ECP), and IL-5 in nasal secretions, eotaxin-3, thymus and activation-regulated chemokine, periostin, and total IgE in blood, and leukotriene E4 in urine (75, 76). This evidence concerns the gene RNASE3 and chronic rhinosinusitis with nasal polyps.